Nat. Rev. Nephrol. doi: /nrneph

Slides:

Advertisements

Similar presentations

Nat. Rev. Nephrol. doi: /nrneph

Advertisements

Figure 3 Life expectancy at birth in all countries included

Nat. Rev. Nephrol. doi: /nrneph

Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.

Figure 4 Interplay between acute kidney injury (AKI),

Figure 6 Effects of adiponectin on podocyte function

Figure 5 Inter-relationships between sleep apnoea, CKD and brain injury Figure 5 | Inter-relationships between sleep apnoea, CKD and brain injury. In chronic.

Figure 3 Energy metabolism regulation, cardiovascular and bone disease in CKD Figure 3 | Energy metabolism regulation, cardiovascular and bone disease.

Figure 6 Differences in glycaemic control with the study drug

Figure 6 Approach to drug management in patients with acute kidney disease (AKD) Figure 6 | Approach to drug management in patients with acute kidney disease.

Figure 4 Expression of coagulation protease receptors in renal cells

Figure 4 Interactions between adipose, the microbiome and kidney

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Mechanisms of kidney injury in the setting of obesity

Nat. Rev. Endocrinol. doi: /nrendo

Figure 2 Physiological changes in the renal system in pregnancy

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Proinflammatory mechanisms in CKD

Figure 1 Role of the kidney in glucose homeostasis

Figure 1 Model of mechanosensation through primary cilia

Figure 3 The fat–intestine–kidney axis

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Global rates of sodium, fruit, and vegetable intake

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 6 The bioavailability of phosphate differs according to the protein source Figure 6 | The bioavailability of phosphate differs according to the.

Figure 7 The efficacy of phosphate-binder therapy

Figure 3 Putative actions of glucagon-like peptide 1 (GLP-1)

Figure 2 Expression of complement activation products in renal samples

Figure 5 Risk factor control in the intensive treatment group

Figure 2 The network of chronic diseases and their mutual influences

Figure 2 Three distinct mechanisms of activation of

Figure 1 The burden of chronic kidney disease (CKD)

Figure 3 Societal costs for the care of patients with chronic kidney disease in the UK Figure 3 | Societal costs for the care of patients with chronic.

Figure 2 Glomerular pathology in mice and humans with diabetic nephropathy Figure 2 | Glomerular pathology in mice and humans with diabetic nephropathy.

Figure 2 Podocyte dysfunction is a common feature of renal injury

Figure 1 Sequential impact of diabetes platforms, genetic backgrounds and accelerators on albuminuria and kidney pathology in mouse models of diabetic.

Figure 1 Acute kidney injury and chronic kidney disease

Figure 4 The gut–kidney axis, inflammation and cardiovascular disease in CKD Figure 4 | The gut–kidney axis, inflammation and cardiovascular disease in.

Figure 2 The continuum of acute kidney injury (AKI),

Figure 4 Model of changes in the serum levels

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Cardiovascular risk and disease across the life-course

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Changes in relative plasma volume (RPV)

Figure 2 Global cost of HF per capita in 2012

Figure 4 The molecular configuration of the CD20 molecule

in the UK (1961–2012), France (1961–2014) and Italy (1961–2010)

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Challenges for big data applications in cardiovascular care

Figure 3 Hypothetical trajectories of acute kidney disease (AKD)

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Serum phosphate level is associated with

Figure 3 Regulation of TGF-β1/Smad signalling by microRNAs (miRs) in tissue fibrosis Figure 3 | Regulation of TGF-β1/Smad signalling by microRNAs (miRs)

Figure 1 The relationship between health fitness and pathogen load

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Figure 2 Biologics that target CD4+ T helper (TH)-cell subsets

Figure 4 The complement drug development pipeline

Figure 1 Patient, facility, health-care system and industry factors

Figure 4 Intracellular distribution and

Figure 1 Overall worldwide prevalence ranges for SLE

Figure 1 Worldwide distribution of disease burden attributable to environmental risks in 2012 Figure 1 | Worldwide distribution of disease burden attributable.

Figure 3 Global iodine status and mandatory salt iodization

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Relationships between genetic variants, quantitative traits and diseases Figure 1 | Relationships between genetic variants, quantitative traits.

Presentation transcript:

Nat. Rev. Nephrol. doi:10.1038/nrneph.2016.181 Figure 3 Factors that could improve access to and expertise in peritoneal dialysis Figure 3 | Factors that could improve access to and expertise in peritoneal dialysis. Each country has unique factors that will determine the areas that must be prioritized to improve the availability and effectiveness of peritoneal dialysis. The three main areas that could facilitate such improvement are organization of health care, financial incentives and research and education. Li, P. K.-T. et al. (2016) Changes in the worldwide epidemiology of peritoneal dialysis Nat. Rev. Nephrol. doi:10.1038/nrneph.2016.181